Shilpa Therapeutics

Shilpa Therapeutics is an India-based pharmaceutical company focused on oral thin-film and orally disintegrating strip formulations. The company appears to operate primarily as a specialty formulation and manufacturing business rather than a clinical-stage biotech, with commercialized products spanning antiemetic, gastrointestinal, erectile dysfunction, neuropathy, asthma, and vitamin supplementation categories. Shilpa Therapeutics is part of the Shilpa Medicare group and has been described as a wholly owned subsidiary of Shilpa Medicare, although a court-approved amalgamation into the parent was sanctioned in February 2026 and was pending effectiveness upon ROC filing. Its differentiating capability is orally disintegrating strip technology, which the company has promoted as a pioneering platform in India. Publicly available evidence does not indicate a novel biologics pipeline or target-driven R&D program typical of venture biotech companies.